Amalia Ruiz

Dr. Amalia Ruiz

Institute of Cancer Therapeutics, Bradford, UK
orcid
Lecturer in Biochemistry and Pharmacology

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2013 in Nanoscale
Verified
Journal Article
Closed access
PDF file
ARAmalia Ruiz
Amalia Ruiz
YHY. Hernández
Y. Hernández
CCC. Cabal
C. Cabal
EDEvelio R. Gonzalez Dalmau
Evelio R. Gonzalez Dalmau
SVSabino Veintemillas-Verdaguer
Sabino Veintemillas-Verdaguer
MMMaría del Puerto Morales
María del Puerto Morales
The influence of polyethylene glycol (PEG) grafting on the pharmacokinetics, biodistribution and elimination of iron oxide nanoparticles is studied in this work. Magnetite nanoparticles (12 nm) were obtained via thermal decomposition of an iron coordination complex as a precursor. Particles were coated with meso-2,3-dimercaptosuccinic acid (DMSA) and conjugated to PEG-derived molecules by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC) chemistry. Using a rat model, we explored the nanoparticle biodistribution pattern in blood and in different organs (liver, spleen and lungs) after intravenous administration of the product. The time of residence in blood was measured from the evolution of water proton relaxivities with time and Fe analysis in blood samples. The results showed that the residence time was doubled for PEG coated nanoparticles and consequently particle accumulation in liver and spleen was reduced. Post-mortem histological analyses showed no alterations in the liver and confirm heterogeneous distribution of NPs in the organ, in agreement with magnetic measurements and iron analysis. Finally, by successive magnetic resonance images we studied the evolution of contrast in the liver and measured the absorption, time of residence and excretion of nanoparticles in the liver during a one month period. On the basis of these results we propose different metabolic routes that determine the fate of magnetic nanoparticles.

1 May 2013 in Acta Biomaterialia
Verified
Journal Article
Closed access
ARAmalia Ruiz
Amalia Ruiz
GSGorka Salas
Gorka Salas
MCM. Calero
M. Calero
YHY. Hernández
Y. Hernández
AVA. Villanueva
A. Villanueva
MMMaría del Puerto Morales
María del Puerto Morales

1 August 2019 in Advanced Functional Materials
Verified
Journal Article
Open access
PDF file
Cristina MartínCristina Martín
Cristina Martín
ARAmalia Ruiz
Amalia Ruiz
SKSandeep Keshavan
Sandeep Keshavan
GRGiacomo Reina
Giacomo Reina
DMDiane Murera
Diane Murera
Alberto BiancoAlberto Bianco
Alberto Bianco
The design of multifunctional materials able to both selectively deliver a drug into cells in a targeted manner and display an enhanced propensity for biodegradation is an important goal. Here, graphene oxide (GO) is functionalized with the chemotactic peptide N‐formyl‐methionyl‐leucyl‐phenylalanine (fMLP) known to interact with the formyl peptide receptor, which is expressed in different cancer cells, including cervical carcinoma cells. This study highlights the ability of GOfMLP for targeted drug delivery and cancer cell killing and the subsequent degradation capacity of the hybrid. Biodegradation is assessed via Raman spectroscopy and transmission electron microscopy. The results show that GOfMLP is susceptible to faster myeloperoxidase‐mediated degradation. The hybrid material, but not GO, is capable of inducing neutrophil degranulation with subsequent degradation, being the first study showing inducible neutrophil degradation by the nanomaterial itself with no prior activation of the cells. In addition, confocal imaging and flow cytometry using HeLa cells demonstrate that GOfMLP is able to deliver the chemotherapeutic agent doxorubicin faster into cells, inducing higher levels of apoptosis, when compared to nonfunctionalized GO. The results reveal that GOfMLP is a promising carrier able to efficiently deliver anticancer drugs, being endowed with the ability to induce its own biodegradation.

26 August 2015 in Nanoscale
Verified
Journal Article
Closed access
PDF file
ARAmalia Ruiz
Amalia Ruiz
LGL. Gutiérrez
L. Gutiérrez
PCPaolin Rocio Cáceres-Vélez
Paolin Rocio Cáceres-Vélez
DSD. Santos
D. Santos
BCBraun Chaves
Braun Chaves
MMMaría del Puerto Morales
María del Puerto Morales
Long-term in vivo studies in murine models have shown that DMSA-coated nanoparticles accumulate in spleen, liver and lung tissues during extended periods of time (at least up to 3 months) without any significant signs of toxicity detected. During that time, nanoparticles undergo a process of biotransformation either by reducing the size or the particle aggregation or both. Using a rat model, we have evaluated the transformations of magnetic nanoparticles injected at low doses. Particles with two different coatings, dimercaptosuccinic acid (NP-DMSA) and polyethylene glycol (NP-PEG-(NH2)2) have been administered to animals, to evaluate the role of coating in the degradation of the particles. We have found that low doses of magnetic nanoparticles are quickly metabolized by the animals. In fact, using a nanoparticle dose four times lower than in previous experiments, NP-DMSA were not observed 24 h after the administration either in the liver or in the lungs. Interestingly, an increased amount of ferritin, the iron storage protein, was observed in liver tissues from rats that were treated with the low dose of NP-DMSA in comparison with the control ones, suggesting a rapid metabolization of the particles into ferritin iron. On the other side we have found that, NP-PEG-(NH2)2 are still detectable in several organs 24 h after their administration at low doses. Probably, due to the longer circulation times of the NP-PEG-(NH2)2, there is a delay in the arrival of the particles to the tissue and this is the reason why we are able to see the particles 24 h post-administration. PEG coating could also be protecting the nanoparticles from rapid degradation of the reticuloendothelial system. Knowledge on the biodistribution, circulation time and degradation processes is required to gain a better understanding of the safety evaluation of this kind of nanomaterial for biomedical applications.

22 October 2014 in Journal of Nanoparticle Research
Verified
Journal Article
Closed access
PDF file
ARAmalia Ruiz
Amalia Ruiz
PMPaulo César Morais
Paulo César Morais
RARicardo Bentes de Azevedo
Ricardo Bentes de Azevedo
ZLZulmira G. M. Lacava
Zulmira G. M. Lacava
AVAngeles Villanueva
Angeles Villanueva
MMMaría del Puerto Morales
María del Puerto Morales

29 January 2019 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
GRGiacomo Reina
Giacomo Reina
ARAmalia Ruiz
Amalia Ruiz
DMDiane Murera
Diane Murera
Yuta NishinaYuta Nishina
Yuta Nishina
Alberto BiancoAlberto Bianco
Alberto Bianco
The last decade has seen an increase in the application of graphene oxide (GO) in the biomedical field. GO has been successfully exploited for its ability to deliver many kinds of drugs into target cells. However, GO toxicity assessment is still controversial. Several studies demonstrated that GO protein coating is crucial to alleviate the material’s toxicity. Besides, coronation leads to the formation of big agglomerates, reducing the cellular uptake of the material and thus its therapeutic efficiency. In this work, we propose a simple and efficient method based on rapid (Ultra-Turrax, UT) mixing to control protein corona formation. Using UT protocol, we were able to reduce GO agglomeration in the presence of proteins and to obtain stable GO dispersions in cell culture media. By labelling GO with luminescent nanoparticles (QDs), we studied the GO internalization kinetic and efficiency. Comparing the “classic” and the UT protocols, we found that the latter allows a faster and more efficient internalization both in macrophages and HeLa cells without affecting cell viability. We believe that the use of UT protocol will be interesting and suitable for the preparation of next generation GO-based drug delivery platforms.